Virica was founded in 2018 based on a decade of research in the laboratory of Dr. Jean-Simon Diallo at the Ottawa Hospital Research Institute.
Dr. Diallo was investigating novel oncolytic viral therapies (OVTs) and recognized the need for VSEs to enhance the effectiveness of OVTs. After researching and developing VSEs in the OVT space, Dr. Diallo recognized how broadly applicable their attributes would be in other areas like gene therapy and vaccine production. Recent influenza outbreaks and the COVID-19 pandemic highlight the need for scalability in the production of vaccines. Virica has the products and experience to combat these challenges.